Further study identified β-catenin capacity as an immunohistochemical surrogate of CTNNB1 exon 3 mutations, showing that β-catenin expression, particularly the nuclear expression possesses a good prognostic factor for endometrial carcinoma and may reflect the mutation of CTNNB1 gene [14]. This evidence concerns the gene CTNNB1 and endometrial carcinoma.